TOPX Summit
TOPX Summit
Sanne Weijzen | VP Corporate Strategy and Head EU Operations, Neogene Therapeutics
Sanne Weijzen, Ph.D., is the Vice President, Corporate Strategy and EU Operations at Neogene Therapeutics. Dr. Weijzen has more than 20 years of combined academic and biotech industry experience. Before joining Neogene, she spent 4 years as a COO of Scenic Biotech, where she was responsible for finance, HR, IP and legal, while building the company from the ground up.
Previously, Dr. Weijzen worked as consultant advising early-stage biotech companies on business strategy, financing, IP, and operations. She started her industry career at Aglaia Biomedical Ventures, investing in early-stage oncology companies, where she ultimately became partner.
Dr. Weijzen earned her master’s degree in Biomedical Sciences from the University of Leiden, the Neterlands and did her Ph.D. research at Cardinal Bernadin Cancer Center, Loyola University Chicago in Tumor Immunology in the lab of Prof. Martin Kast. She completed her post-doctoral fellowship in molecular cancer cell signaling at the University of Utrecht.
Neogene Therapeutics
Neogene Therapeutics is a global, preclinical stage biotechnology company pioneering the development of next generation, fully individualized engineered T cell therapies for a broad spectrum of cancers.
While engineered T cell therapies have transformed the treatment paradigm for patients with hematologic malignancies, effective T cell therapy is limited for patients with solid cancers. To truly revolutionize patient outcomes, we need a new approach to effectively treat and potentially cure solid cancers. We believe that through a fully individualized approach using patient-specific TCRs to target neoantigens, engineered T cell therapy can become broadly accessible to these patients.
Our proprietary neoantigen T cell receptor (TCR) discovery and T cell engineering platform identifies TCR genes with specificity for neoantigens – found exclusively on cancer cells as a result of cancer-associated DNA mutations. Neogene aims to overcome the limitations of current T cell therapies by using these neoantigen specific TCRs in fully individualized engineered T cell therapies.
Neogene Therapeutics is a global, preclinical stage biotechnology company pioneering the development of next generation, fully individualized engineered T cell therapies for a broad spectrum of cancers.
While engineered T cell therapies have transformed the treatment paradigm for patients with hematologic malignancies, effective T cell therapy is limited for patients with solid cancers. To truly revolutionize patient outcomes, we need a new approach to effectively treat and potentially cure solid cancers. We believe that through a fully individualized approach using patient-specific TCRs to target neoantigens, engineered T cell therapy can become broadly accessible to these patients.
Our proprietary neoantigen T cell receptor (TCR) discovery and T cell engineering platform identifies TCR genes with specificity for neoantigens – found exclusively on cancer cells as a result of cancer-associated DNA mutations. Neogene aims to overcome the limitations of current T cell therapies by using these neoantigen specific TCRs in fully individualized engineered T cell therapies.
| Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
| Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | | |
© Copyright 2020 by Hyphen Projects